Cenforce is produced by Centurion Laboratories in several sildenafil strengths, including 100mg, 150mg, and 200mg. Understanding what the differences between these doses actually mean – pharmacologically and from a safety perspective – requires understanding how sildenafil doses are structured in licensed clinical practice.
How sildenafil dosing works clinically
Sildenafil follows a dose-response relationship: within the therapeutic range, higher doses produce stronger PDE5 inhibition, which can increase efficacy – but also increases the likelihood and severity of side effects. There is a ceiling to this relationship. Beyond a certain dose, additional sildenafil does not produce meaningfully better therapeutic outcomes but does increase side effect risk.
UK clinical guidelines and the MHRA’s approved product characteristics reflect this. Sildenafil for erectile dysfunction is licensed in the UK at three doses: 25mg, 50mg, and 100mg. The 50mg dose is the standard starting point. Men who do not achieve adequate response at 50mg may be increased to 100mg under clinical guidance. The 25mg dose is used in men who are more sensitive to the drug or who are taking certain other medications.
Cenforce 100mg in the context of licensed doses
Cenforce 100mg contains the same quantity of sildenafil as the maximum licensed dose approved by the MHRA for erectile dysfunction. From a dose perspective, 100mg of sildenafil is 100mg of sildenafil regardless of the manufacturer.
The difference between Cenforce 100mg and licensed generic sildenafil 100mg is not the dose – it is the regulatory framework. Licensed products have been assessed for quality, safety, and efficacy by the MHRA. Cenforce 100mg has not undergone this UK regulatory process, meaning there is no independent verification of actual sildenafil content, tablet purity, or manufacturing standards to UK requirements.
Cenforce 150mg: above the licensed dose
Cenforce 150mg contains 50mg more sildenafil than the maximum dose approved by the MHRA. There is no licensed 150mg sildenafil product for erectile dysfunction in the UK. This dose has not been evaluated in the regulatory process that establishes what is safe and effective for UK adults.
Pharmacologically, 150mg of sildenafil produces stronger PDE5 inhibition than 100mg. Whether this translates to meaningfully better outcomes for any individual man is not established by clinical evidence at this dose level. What is established is that side effects become more pronounced at higher doses:
- Hypotension – lowering of blood pressure – is more marked at higher doses
- Headache and facial flushing are more common
- Visual disturbances including blurred vision and the blue tinge effect are more likely
- Priapism – a prolonged, painful erection requiring urgent medical attention – becomes a more significant risk
Cenforce 200mg: twice the licensed maximum
Cenforce 200mg contains twice the maximum dose of sildenafil approved by the MHRA. It sits well outside the dose range that has been evaluated in the regulatory process for safety and efficacy in the UK. The side effect risks noted at 150mg are amplified further at 200mg.
The blood pressure effect is particularly significant. Sildenafil lowers blood pressure as part of its mechanism of action. At supratherapeutic doses, this effect is greater. For men who are also taking antihypertensive medications – which are common in the age groups most likely to be experiencing erectile dysfunction – the cumulative blood pressure effect can be clinically significant.
Why the dose differences matter beyond pharmacology
When an unlicensed product is purchased without clinical oversight, there is no mechanism to screen for the conditions and medications that affect sildenafil safety. The higher the dose, the narrower the margin for error:
- A man with undiagnosed hypertension taking antihypertensives faces greater blood pressure risk at 200mg than at 100mg
- A man who has taken a recreational drug containing nitrates faces life-threatening risk at any sildenafil dose, but the risk is greater at higher doses
- A man with an undiagnosed retinal condition faces greater visual risk
These are not theoretical concerns. They are the reasons that sildenafil – even at licensed doses – is a prescription-only medicine requiring clinical assessment before use.
What to do if a lower dose is not effective
The clinically appropriate response to inadequate response at licensed doses is a GP consultation – not escalation to an unlicensed higher dose. A GP can:
- Assess whether underlying conditions such as diabetes, vascular disease, or hormonal imbalance are reducing sildenafil’s effectiveness
- Review whether the medication has been used correctly – timing relative to food and sexual arousal significantly affects response
- Consider whether tadalafil might be more appropriate for the individual
- Refer to a specialist if the standard management pathway is insufficient
Frequently asked questions
Is there a meaningful clinical difference between 100mg and 150mg sildenafil?
Pharmacologically, higher doses produce stronger PDE5 inhibition. However, the dose-response curve for sildenafil flattens as the dose increases – the incremental therapeutic gain from 100mg to 150mg is less than from 25mg to 50mg, while side effect risk continues to increase linearly.
Could a GP ever prescribe more than 100mg sildenafil?
No. 100mg is the maximum licensed dose for ED in the UK. A GP can only prescribe within the licensed dose range for approved indications. Any use beyond 100mg would be outside licensed prescribing.
What is Cenforce D?
Cenforce D is a combination product containing sildenafil 100mg and dapoxetine 60mg – targeting both erectile dysfunction and premature ejaculation simultaneously. It is not licensed in the UK. Dapoxetine is available separately as the licensed product Priligy for premature ejaculation.
Are there other sildenafil manufacturers besides Centurion?
Yes. Sildenafil is manufactured by numerous pharmaceutical companies globally. In the UK, licensed generic sildenafil is available from multiple MHRA-approved manufacturers. The licensing status – not the manufacturer’s origin – is what determines regulatory oversight.
